- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Etiam partners with French healthcare network
Etiam Cooperative Medical Imaging Products signed a partnership agreement with Cegetel, a healthcare network in France, to equip all of Cegetel’s 16,000 subscribers with a basic version of
Etiam Cooperative Medical Imaging Products signed a partnership agreement with Cegetel, a healthcare network in France, to equip all of Cegetels 16,000 subscribers with a basic version of Etiams Mediem medical e-mail system, called Mediem Box, by the end of this year. This is the first commercial implementation of Mediem, a multimedia e-mail program that allows users to e-mail structured correspondence, free text notes or letters, medical imaging files, annotations, and audio messages such as dictated reports. Mediem employs Java code and is fully compatible with DICOM, according to the Rennes, France-based firm. Cegetel expects to expand its subscriber base to 50,000 this year; all new subscribers will also gain the Mediem capability.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
